Surrogate markers for cardiovascular disease: Structural markers

Circulation

Volumn 109, Issue 25, 2004, Pages

  Mancini, G B John ^b   Dahlöf, Björn ^c   Díez, Javier ^d   Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BLOOD CLOTTING FACTOR 5 LEIDEN; C REACTIVE PROTEIN; CALCIUM; CHOLESTEROL; COLLAGEN; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; INSULIN; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

AGING; ALCOHOL CONSUMPTION; ARTERY MEDIA; ATHEROSCLEROSIS; B SCAN; CARDIOVASCULAR DISEASE; CAROTID ARTERY; DIABETES MELLITUS; DISEASE MARKER; ELECTRON BEAM TOMOGRAPHY; ETHNOLOGY; FAMILY HISTORY; GENDER; GLUCOSE INTOLERANCE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERLIPIDEMIA; INTIMA; OBESITY; OPHTHALMOSCOPY; PATHOPHYSIOLOGY; POSTMENOPAUSE; PRIORITY JOURNAL; RACE; REVIEW; RISK FACTOR; SMOKING;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CAROTID ARTERY DISEASES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; TUNICA INTIMA; TUNICA MEDIA;

EID: 3042798821     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74:1399-1406.
2. Riley WA, Bames RW, Applegate WB, et al. Reproducibility of noninvasive ultrasonic measurement of carotid atherosclerosis: the Asymptomatic Carotid Artery Plaque Study. Stroke. 1992;23:1062-1068.
3. Mukherjee D, Yadav JS. Carotid artery intimal-medial thickness: Indicator of atherosclerotic burden and response to risk factor modification. Am Heart J. 2002;144:753-759.
4. Levenson J, Simon A. Phase III and phase IV trials: noninvasive assessment of efficacy endpoints in vessel walls. Am J Cardiol. 1998;81:67F-68F.
5. Aminbakhsh A, Mancini GBJ. Carotid intima-media thickness measurements: what defines an abnormality? A systematic review. Clin Invest Med. 1999;22:149-157.
6. Wang TJ, Nam B-H, Wilson PWF, et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002;22:1662-1667.
7. Zureik M, Touboul PJ, Nomithon-Kopp C, et al. Differential association of common carotid intima-media thickness and carotid atherosclerotic plaques with parental history of premature death from coronary heart disease: the EVA Study. Arterioscler Thromb Vasc Biol. 1999;19:366-371.
8. Ebrahim S, Papacosta O, Whincup P, et al. Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke. 1999;30:841-850.
9. Li R, Duncan BB, Metcalf PA, et al. B-mode-detected carotid artery plaque in a general population. Stroke. 1994;25:2377-2383.
10. Aminbakhsh A, Frohlich J, Mancini GBJ. Detection of early atherosclerosis with B mode carotid ultrasonography: Assessment of a new quantitative approach. Clin Invest Med. 1999;22:265-274.
11. Chan SY, Mancini GBJ, Kuramoto L, et al. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol. 2003;42:1037-1043.
12. Spence JD, Eliasziw M, DiCicco M, et al. Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke. 2002;33:2916-2922.
13. Anand SS, Yusuf S, Vuksan V, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet. 2000;356:279-284.
14. Bensen JT, Li R, Hutchinson RG, et al. Family history of coronary heart disease and pre-clinical carotid artery atherosclerosis in African-Americans and whites: Atherosclerosis Risk in Communities. Genet Epidemiol. 1999;16:165-178.
15. Bonithon-Kopp C, Scarabin PY, Taquet A, et al. Risk factors for early carotid atherosclerosis in middle-aged French women. Arterioscler Thromb. 1991;11:966-972.
16. Davis PH, Dawson JD, Riley WA, et al. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age. The Muscatine study. Circulation. 2001;104:2815-2819.
17. Ferrieres J, Elias A, Ruidavets JB, et al. Carotid intima-media thickness and coronary heart disease risk factors in a low-risk population. Hypertension. 1999;17:743-748.
18. Folsom AR, Eckfeldt JH, Weitzman S, et al. Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Stroke. 1994;25:66-73.
19. Fox CS, Polak JR, Chazaro I, et al. Genetic and environmental contributions to atherosclerosis phenotypes in men and women: heritability of carotid intima-media thickness in the Framingham Heart Study. Stroke. 2003;34:397-401.
20. Kuller L, Borhani N, Furberg C, et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the cardiovascular health study. Am J Epidemiol. 1994;139:1164-1179.
21. Lassila HC, Tyrrell KS, Matthews KA, et al. Prevalence and determinants of carotid atherosclerosis in healthy postmenopausal women. Stroke. 1997;28:513-517.
22. Mannami T, Konishi M, Baba S, et al. Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city: the Suita Study. Stroke. 1997;28:518-525.
23. Okamura T, Kitamura A, Moriyama Y, et al. Plasma level of homocysteine is correlated to extracranial carotid-artery atherosclerosis in non-hypertensive Japanese. J Cardiovasc Risk. 1999;6:371-377.
24. O'Leary DH, Polak JF, Kronmal RA, et al. Thickening of the carotid wall: a marker for atherosclerosis in the elderly? Stroke. 1996;27:224-231.
25. O'Leary DH, Anderson KM, Wolf PA, et al. Cholesterol and carotid atherosclerosis in older persons: the Framingham Study. Ann Epidemiol. 1992;2:147-153.
26. Prati P, Vanuzzo D, Casaroli M, et al. Prevalence and determinants of carotid atherosclerosis in a general population. Stroke. 1992;23:1705-1711.
27. Salonen R, Seppanen K, Rauramaa R, et al. Prevalence of carotid atherosclerosis and serum cholesterol levels in eastern Finland. Arteriosclerosis. 1988;8:788-792.
28. Sorof JM, Alexandrov AV, Cardwell G, et al. Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure. Pediatrics. 2003;111:61-66.
29. Swan L, Bimie DH, Inglis G, et al. The determination of carotid intima medial thickness in adults: a population-based twin study. Atherosclerosis. 2003;166:137-141.
30. Voutilainen S, Alfthan G, Nyyssonen K, et al. Association between elevated plasma total homocysteine and increased common carotid artery wall thickness. Ann Intern Med. 1998;30:300-306.
31. Bonora E, Kiechl S, Oberhollenzer F, et al. Impaired glucose tolerance, type II diabetes mellitus and carotid atherosclerosis: Prospective results from the Bruneck study. Diabetologia. 2000;43:156-164.
32. Chambless LE, Folsom AR, Davis V, et al. Risk factors for progression of common carotid atherosclerosis: The Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol. 2002;155:38-47.
33. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997;146:483-494.
34. Crouse JR 3d, Tang R, Espeland MA, et al. Associations of extracranial carotid atherosclerosis progression with coronary status and risk factors in patients with and without coronary artery disease. Circulation. 2002;106:2061-2066.
35. Salonen R, Salonen JT. Progression of carotid atherosclerosis and its determinants: A population-based ultrasonography study. Atherosclerosis. 1990;81:33-40.
36. Willeit J, Kiechl S, Oberhollenzer F, et al. Distinct risk profiles of early and advanced atherosclerosis: Prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2000;20:529-544.
37. van der Meer IM, de Maat MPM, Hak E, et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree. The Rotterdam Study. Stroke. 2002;33:2750-2755.
38. Craven TE, Ryu JE, Espeland MA, et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis: a case-control study. Circulation. 1990;82:1230-1242.
39. Crouse JR 3d, Craven TE, Hagaman AP, et al. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. Circulation. 1995;92:1141-1147.
40. Wofford JL, Kahl FR, Howard GR, et al. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb. 1991;11:1786-1794.
41. Burke GL, Evans GW, Riley WA, et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. Stroke. 1995;26:386-391.
42. Adam MR, Nakagomi A, Keech A, et al. Carotid intima-media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation. 1995;92:2127-2134.
43. Visona A, Pesavento R, Lusiani L, et al. Intimal medial thickening of common carotid artery as indicator of coronary artery disease. Angiology. 1996;47:61-66.
44. Holaj R, Spacil J, Petrasek J, et al. Intima-media thickness of the common carotid artery is the significant predictor of angiographically proven coronary artery disease. Can J Cardiol. 2003;19:670-676.
45. Davis PH, Dawson JD, Mahoney LT, et al. Increased carotid intimal-medial thickness and coronary calcification are related in young and middle-aged adults. The Muscatine Study. Circulation. 1999;100:838-842.
46. Nagai Y, Metter EJ, Earley CJ, et al. Increased carotid artery intimal-medial thickness in asymptomatic older subjects with exercise-induced myocardial ischemia. Circulation. 1998;98:1504-1509.
47. Giral P, Bruckert E, Dairou F, et al. Usefulness in predicting coronary artery disease by ultrasonic evaluation of the carotid arteries in asymptomatic hypercholesterolemic patients with positive exercise stress tests. Am J Cardiol. 1999;84:14-17.
48. Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb. 1991;11:1245-1249.
49. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction. The Rotterdam Study. Circulation. 1997;96:1432-1437.
50. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14-22.
51. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262-269.
52. Mancini GBJ. Carotid intima-media thickness as a measure of vascular target organ damage. Curr Hypertens Rep. 2000;2:71-77.
53. Lonn E. Use of carotid ultrasound to stratify risk. Can J Cardiol. 2001;17:22A-25A.
54. Maroo A, O'Donnell CJ. Current practice and future promise for clinical noninvasive measurements of subclinical atherosclerotic disease in the elderly. Am J Geriatric Cardiol. 2002;11:108-118.
55. Furberg CD, Adams HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687.
56. Crouse JR 3d, Byington RP, Bond MG, et al. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol. 1995;75:455-459.
57. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effects of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92:1758-1764.
58. MacMahon S, Sharpe N, Gamble G, et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis. Results of the LIPID atherosclerosis substudy. Circulation. 1998;97:1784-1790.
59. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106:2055-2060.
60. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510.
61. Lonn EM, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103:919-925.
62. Byington RP, Furberg CD, Herrington DM, et al. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease. HERS B-mode substudy. Arterioscler Thromb Vasc Biol. 2002;22:1692-1697.
63. MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol. 2000;36:438-443.
64. Redberg RF, Greenland P, Fuster V, et al. Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group III: risk assessment in persons with diabetes. Circulation. 2002;105:E144-E152.
65. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
66. Devereux RB, Agabiti-Rosei E, Dahlöf B, et al. Regression of left ventricular hypertrophy as a surrogate endpoint for morbid events in hypertension treatment trials. J Hypertens. 1996;14(suppl 2):S95-S102.
67. Devereux RB, Okin PM, Roman MJ. Left ventricular hypertrophy as a surrogate endpoint in hypertension. Clin Exp Hypertens. 1999;21:583-593.
68. Dahlöf B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypetiens. 2001;14:174-182.
69. Dahlöf B. Structural cardiovascular changes in essential hypertension. Studies on the effects of antihypertensive therapy. Blood Pressure. 1992;1(suppl 6):1-75.
70. nd ed. New York: Raven Press; 1995:1969-1985.
71. Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens. 1991;9:3-5.
72. Dahlöf B, Herlitz H, Aurell M, et al. Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system. Am J Hypertens. 1992;5: 900-911.
73. Everett AD, Tufro-McReddie A, Fisher A, et al. Angiotensin inhibitors regressed cardiac hypertrophy and transforming growth factor-β 1 expression. Hypertension. 1994;23:587-592.
74. Pachori AS, Numan MT, Ferrario CM, et al. Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. Hypertension. 2002;39:969-975.
75. Mukherjee D, Sen S. Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats. Circ Res. 1990;67:1474-1480.
76. Yang CM, Kandaswamy V, Young D, et al. Changes in collagen phenotypes during progression and regression of cardiac hypertrophy. Cardiovasc Res. 1997;36:236-245.
77. Weber KT, Brilla CG. Pathological hypertrophy and cardiac intersfitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
78. Weber KT, Brilla CG. Factors associated with reactive and reparative fibrosis of the myocardium. Basic Res Cardiol. 1992;87(suppl 7):291-301.
79. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141:334-341.
80. Molloy TJ, Okin PM, Devereux RB, et al. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol. 1992;20:1180-1186.
81. Okin PM, Roman MJ, Devereux RB, et al. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995;25:417-423.
82. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. J Am Coll Cardiol. 1998;31:383-390.
83. Levy D, Salomon M, D'Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-1793.
84. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615-1621.
85. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:45-54.
86. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
87. Liao Y, Cooper RS, McGee DL, et al. The relative effects of left ventricular hypertrophy, coronary artery disease and ventricular dysfunction on survival among black adults. JAMA. 1995;273:1592-1597.
88. Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580-586.
89. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161-186.
90. Dahlöf B, Devereux RB, Julius S, et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: baseline characteristics of 9,194 patients with left ventricular hypertrophy. Hypertension. 1998;32:989-997.
91. Wachtell K, Bella JN, Liebson PR, et al. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study. Hypertension. 2000;35(1 pt 1):6-12.
92. Schillaci G, Verdecchia P, Borgioni C, et al. Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol. 1994;74:714-719.
93. Norman JE Jr., Levy D. Improved electrocardiographic detection of echocardiographic left ventricular hypertrophy: results of a correlated data base approach. J Am Coll Cardiol. 1995;26:1022-1029.
94. Devereux RB, Bella J, Boman K, et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. Blood Pressure. 2001;10:74-82.
95. Palmieri V, Dahlöf B, DeQuattro V, et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol. 1999;34: 1625-1632.
96. Bikkina M, Levy D, Evans JC, et al. Left ventricular mass and risk of stroke in an elderly cohort: the Framingham Heart Study. JAMA. 1994;272:33-36.
97. Ghali JK, Liao Y, Simmons R, et al. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med. 1992;117:831-836.
98. Bolognese L, Dellavesa P, Rossi L, et al. Prognostic value of left ventricular mass in uncomplicated acute myocardial infarction and one-vessel coronary artery disease. Am J Cardiol. 1994;73:1-5.
99. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793-801.
100. Sokolow M, Perloff D. Prognosis of essential hypertension treated conservatively. Circulation. 1961;23:697-713.
101. Breslin DJ, Gifford RW Jr., Fairbairn JF 2nd. Essential hypertension: a twenty-year follow-up study. Circulation. 1966;33:87-97.
102. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105:173-178.
103. Levy D, Garrison RJ, Savage DD, et al. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: the Framingham Study. Ann Intern Med. 1989;110:101-107.
104. MacMahon S, Collins G, Rautaharju P, et al. Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1989;63:202-210.
105. Sullivan JM, Vander Zwaag RV, el-Zeky F et al. Left ventricular hypertrophy: effect on survival. J Am Coll Cardiol. 1993;22:508-513.
106. Kannel WB, Abbott RD. A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction: the Framingham study. Am Heart J. 1986;111:391-397.
107. Isles CG, Walker LM, Beevers GD, et al. Mortality in patients of the Glasgow blood pressure clinic. J Hypertens. 1986;4:141-156.
108. Aronow WS, Epstein S, Koenigsberg M, et al. Usefulness of echocardiographic left ventricular hypertrophy, ventricular tachycardia and complex ventricular arrhythmias in predicting ventricular fibrillation or sudden cardiac death in elderly patients. Am J Cardiol. 1988;62:1124-1125.
109. Silberberg JS, Barre PE, Prichard SS, et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36:286-290.
110. Parfrey PS, Harnett JD, Griffiths SM, et al. The clinical course of left ventricular hypertrophy in dialysis patients. Nephron. 1990;55:114-120.
111. Quinones MA, Weiner DH, Shelton BJ, et al, for the SOLVD Investigators: Echocardiographic predictors of one-year clinical outcome in the Study Of Left Ventricular Dysfunction (SOLVD) Trial and Registry: a study of 1,172 patients [Abstract]. Circulation. 1993;90(suppl I):I304.
112. Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 1995;13:1091-1105.
113. Koren MJ, Ulin RJ Laragh JH, et al. Reduction of left ventricular mass during treatment of essential hypertension is associated with improved prognosis [Abstract]. Am J Hypertens. 1991;4:1A.
114. Yurenev AP, Dyakonova MG, Novikov ID, et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy: multicenter trial. Am J Hypertens. 1992;5(suppl): 182s-189s.
115. Dahlöf B, Devereux RB, de Faire U. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design and methods. Am J Hypertens. 1997;10:705-713.
116. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
117. Okin PM, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events: the LIFE study. Circulation. 2002;106(suppl II):11-477.
118. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program: prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension. 1985;7:105-112.
119. Devereux RB, Wachtell K, Gerdts E, et al. Regression of left ventricular hypertrophy: treatment effects and prognostic implications in the LIFE trial [Abstract]. J Hypertens. 2002:20(suppl 4):S4.
120. Devereux RB, Dahlöf B. Requirements for an informative trial of left ventricular hypertrophy regression. J Hum Hypertens. 1994;8:735-739.
121. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients - a meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
122. Schmieder RE, Schneider MP, Martus P, et al. Reduction of left ventricular hypertrophy (LVH) by antihypertensive therapy: results of a meta-analysis of all double-blind randomized studies. J Am Coll Cardiol. 2001;37:261A-262A.
123. Terpstra WL, May JF, Smit AJ, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001;19:303-309.
124. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomised Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation. 2001;104:1248-1254.
125. Zanchetti A, Ruilope LM, Cuspidi C, et al. Comparative effects of the AVE inhibitor fosinopril and the calcium antagonist amlodipine on left ventricular hypertrophy and urinary albumin excretion in hypertensive patients. Results of FOAM, a multicenter European study [Abstract]. J Hypertens. 2001;19(suppl 2):S92.
126. Gosse P, Scheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5mg versus enalapril 20mg; the LIVE study. J Hypertens. 2000;18:1468-1475.
127. Cuspidi C, Muiesan ML, Valagussa L, et al., on behalf of the CATCH Investigators. Comparative effects of Candesartan and Enalapril on left ventricular hypertrophy in patients with essential hypertension: The Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens. 2002;20:2293-2300.
128. Agabiti Rosei E, Muiesan ML, Trimarco B, et al. Changes of LV mass and ABPM during long-term antihypertensive treatment in ELSA [Abstract]. J Hypertens. 2002;20(suppl 4):S4.
129. Thurmann PA Kenedi P, Schmidt A, et al. Influence of the Angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 1998;98:2037-2042.
130. Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001;19:1167-1176.
131. Dahlöf B, Zanchetti A, Díez J, et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens. 2002;20:1855-1864.
132. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Circulation. 2003;108:684-690.
133. Devereux RB, Boman K, Gerdts E, et al. Left ventricular mass change during treatment and outcome in hypertensive patients with left ventricular hypertrophy: the LIFE trial. J Am Coll Cardiol. 2002;39:464B.
134. Detrano RC, Wong ND, Doherty TM, et al. Coronary calcium does not accurately predict near-term future coronary events in high-risk adults. Circulation. 1999;99:2633-2638.
135. Arad Y, Spadaro LA, Goodman K, et al. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol. 2000;36:1253-1260.
136. Lee TC, O'Malley PG, Feuerstein I, et al. The prevalence and severity of coronary artery calcification on coronary computed tomography in black and white subjects. J Am Coll Cardiol. 2003;41:39-44.
137. Hoff JA, Chomka EV, Krainik AJ, et al. Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults. Am J Cardiol. 2001;87:1335-1339.
138. Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci. 1974;268:336-345.
139. Querejeta R, Varo N, López B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:1729-1735.